Results 221 to 230 of about 10,900 (261)

Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab

Pediatric Infectious Disease Journal, 2015
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants. Palivizumab, a means of passive prophylaxis, relies on patient adherence to ensure therapeutic effectiveness. The objective of this study is to evaluate the association between adherence and the incidence of RSV-associated outcomes and to identify ...
Parco, Chan, Abby, Li, Bosco, Paes, Haben, Abraha, Ian, Mitchell, Krista L, Lanctôt   +5 more
openaire   +2 more sources

Administration of Palivizumab in the NICU

Hospital Pediatrics, 2016
BACKGROUND: The American Academy of Pediatrics recommends palivizumab prophylaxis against respiratory syncytial virus (RSV) for infants at high risk for severe disease within 72 hours of hospital discharge to prevent community-associated RSV.
Neika, Vendetti, Jeffrey S, Gerber, Julia Shaklee, Sammons, Brian T, Fisher, Theoklis E, Zaoutis, Susan E, Coffin   +5 more
openaire   +2 more sources

Questions About Palivizumab (Synagis)

Pediatrics, 1999
To the Editor. A humanized monoclonal antibody designed for the prevention of serious disease attributable to respiratory syncytial virus (RSV) has recently been approved by the Food and Drug Administration (FDA). Palivizumab, manufactured by MedImmune, Inc (Gaithersburg, MD) and marketed as Synagis, is indicated for pediatric patients who are at ...
openaire   +1 more source

Palivizumab (Synagis): Counting “Costs” and Values

Pediatrics, 2000
To the Editor. The continuing reports, letters, and pharmacoeconomic analyses concerning the use of expensive respiratory syncytial virus (RSV) prophylaxis regimens for neonatal intensive care unit (NICU) graduates mark what appears to be a shift in decisional processes for clinicians.1–3 The consideration of cost, although not new in medical or ...
openaire   +2 more sources

Palivizumab

Drugs of the Future, 1998
null Sorbera, L.A., null Rabasseda, X., null Leeson, P.A.   +2 more
openaire   +1 more source

Palivizumab

Reactions Weekly, 2021
openaire   +1 more source

PALIVIZUMAB

Reactions Weekly, 2015
openaire   +2 more sources

Palivizumab

Reactions Weekly, 2020
openaire   +2 more sources

Palivizumab

Reactions Weekly, 2014
openaire   +2 more sources

Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab

European Journal of Pediatrics, 2021
Ayako Chida-Nagai, Hiroki Sato, Itsumi Sato, M. Shiraishi, Daisuke Sasaki, G. Izumi, H. Yamazawa, Kazutoshi Cho, A. Manabe, A. Takeda   +9 more
semanticscholar   +1 more source